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ABSTRACT
Objectives: To evaluate whether dyspareunia is
associated with HIV status in menopausal women and
also to assess which factors are associated with
dyspareunia in a group of HIV-positive menopausal
women.
Methods: A cross-sectional study was conducted with
178 HIV-negative and 128 HIV-positive women aged
40–60 years. The Short Personal Experiences
Questionnaire (SPEQ) was used to collect data.
Sociodemographic, clinical, behavioural and
reproductive factors were evaluated, as well as factors
related to the HIV infection. Dyspareunia was defined as
pain during intercourse. A bivariate analysis and
Poisson multiple regression analysis were performed.
Results: Overall, 41.4% of the HIV-positive women
reported dyspareunia compared with 34.8% of the HIV-
negative women (p=0.242). In the HIV-positive women,
bivariate analysis revealed an association between
dyspareunia and having a steady partner (p=0.047); the
woman’s partner having undergone HIV testing
(p=0.020); vaginal dryness (p<0.001); muscle/joint
pain (p=0.021); physical/emotional violence (p=0.049);
urinary incontinence (p=0.004); and the use of
lamivudine/zidovudine (p=0.048). The Poisson multiple
regression analysis found an association between
dyspareunia and vaginal dryness (prevalence ratio (PR)
=1.96, 95% CI 1.10 to 3.50, p=0.023) and urinary
incontinence (PR=1.86, 95% CI 1.06 to 3.27, p=0.031).
Conclusions: Dyspareunia was common in this group
of HIV-positive women and was associated principally
with vaginal dryness and urinary incontinence. The
importance of treating dyspareunia within the context of
sexual health in this group of women should be
emphasised and appropriate management of this issue
may reduce the likelihood of lesions on the vaginal wall,
which may act as a portal of entry for other infections.
INTRODUCTION
Dyspareunia is defined as persistent or recur-
rent genital pain that occurs just before, during
or after intercourse. It is one of the most
common problems reported by menopausal
women. The variation in the frequency of
dyspareunia probably reflects many issues
including sociocultural aspects, the period of
observation during which the condition was
evaluated (ever, the past year) and the duration
or design of the study under discussion (ques-
tionnaire wording, participants).1
For women of all ages, the pain caused by
dyspareunia often results in distress, impaired
sexual functioning and poor sexual enjoy-
ment, difficulty in relationships and a poorer
quality of life. In postmenopausal women, dys-
pareunia may also intensify personal issues
related to ageing, body image and health.2
As with most of the sexual difficulties faced
by women in midlife and beyond, dyspareunia
is typically considered a consequence of
declining ovarian hormone levels and is
usually attributed to vaginal atrophy;3 however,
other factors may also be involved.4 In fact, psy-
chosexual and biological factors (including
muscular, endocrine, immune, neurological,
vascular and iatrogenic factors) that predis-
pose to, precipitate and perpetuate the condi-
tion may interact with different degrees in the
Strengths and limitations of this study
▪ We have not found studies on dyspareunia in
HIV-positive women.
▪ We have highlighted the importance of vulvova-
ginal atrophy and its association with dyspar-
eunia in middle-aged HIV-positive women.
▪ We have shown that HIV infection was not sig-
nificantly associated with dyspareunia, probably
because HIV-positive women had few HIV-related
symptoms.
▪ The results of this study may help physicians to
focus attention on vulvovaginal atrophy and its con-
sequences in this group of HIV-positive women.
▪ It is a cross-sectional design study.
▪ There were some differences in the clinical
characteristics of the HIV-positive and HIV-negative
women.
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individual woman, contributing to a continuum of symp-
toms of increasing severity, with the potential to impair
sexual intercourse.5 Age,6 depression, anxiety and sexual
dysfunction in the partner4 5 are some of the other factors
associated with dyspareunia. It seems that cognitive–
emotional variables (catastrophisation, depression, anxiety)
are significant predictors of dyspareunia and relationship
adjustment variables were inversely associated with pain
severity.7 Findings also suggest that dyspareunia impacts the
psychosexual adjustment of affected women as well as of
their partners.8
Menopausal women who are HIV positive may present a
unique set of issues that could affect their sexuality. These
issues may include the meaning of their illness, their
quality of life, HIV transmissibility, and the dilemma of
whether or not to disclose the condition to their partner.
Florence et al9 reported sexual dysfunction to be common
in HIV-positive women, principally as a result of their HIV
status and of psychological factors that included depres-
sion, irritability and anxiety. On the other hand, women
with better mental health after HIV diagnosis, a more posi-
tive attitude towards living with HIV, a better quality of life,
fewer HIV-related symptoms and who had never used
injectable drugs were found to have better sexual function-
ing.10 A possible role of antiretroviral drugs in causing
sexual dysfunction has been a matter of debate. While
some studies have suggested that antiretroviral therapy
(ART) indeed plays a role in sexual function, others have
failed to find any such association.11
The majority of studies on dyspareunia have failed to
deal with factors associated with HIV infection, a topic yet
to be fully investigated in HIV-positive women during the
ageing process. Therefore, the objectives of the present
study were to evaluate whether dyspareunia is associated
with HIV status in middle-aged women and to assess the
factors associated with dyspareunia in HIV-positive
middle-aged women.
METHODS
Study design
A cross-sectional study was conducted in 537 women
aged 40–60 years, of whom 273 were HIV-positive and
264 were HIV-negative and screened for inclusion.
Patients were recruited at the infectious diseases and
HIV outpatient clinics (HIV-positive women) and at the
menopausal ambulatory care (HIV-negative women),
both at the Teaching Hospital of the University of
Campinas (UNICAMP). Patients were also invited to par-
ticipate at the infectious diseases outpatient public clinic
(HIV-positive women) in Belo Horizonte. Of these, 178
HIV-negative women and 128 HIV-positive women had
had vaginal intercourse in the previous month and were
willing to answer a questionnaire on dyspareunia. These
women were then admitted to the study.
For inclusion in the HIV-positive group, laboratory con-
firmation of the women’s seropositive status by one of the
recommended tests (ELISA or Western Blot) was required
(all of them had it), while the women recruited to the
HIV-negative group had to have tested negative. The
blood sample tests of HIV-negative and HIV-positive
women were collected at the moment of admission in this
study (follicle stimulating hormone (FSH), luteinising
hormone (LH) and thyroid stimulating hormone for all;
ELISA or Western Blot HIV tests for HIV-negative women;
and Viral load and CD4 cells for HIV-positive women).
Exclusion criteria consisted of nursing mothers, bilaterally
oophorectomised women and those unable to answer
the questionnaire. The evaluation instrument was the
Short Personal Experiences Questionnaire (SPEQ).12 13
Sociodemographic, clinical, behavioural and reproductive
characteristics were assessed as well as issues relating to the
HIV infection and partner-related factors.
Dependent variable
The dependent variable dyspareunia, defined as pain
during sexual intercourse, was graded from 1 to 6, where 1
referred to the absence of pain and 6 to maximum pain.
A score of less than two was considered to represent the
absence of dyspareunia and a score of two or more to rep-
resent the presence of dyspareunia.4 12 13
Independent variables
The independent variables were dichotomised as
follows: HIV status (positive/negative); skin colour
(white/other); marital status (has a stable partner/no
stable partner); schooling (≤7 years/≥8 years); employ-
ment (yes/no); monthly family income (≤US$750/>US
$750); receives pension (yes/no); smokes (yes/never or
ex-smoker); alcohol use (currently drinks or used to
drink/never drank); hot flushes (yes/no); depression
(yes/no); vaginal dryness (yes/no); urinary incontin-
ence (yes/no); weight gain (yes/no); muscle and joint
pain (yes/no); self-perception of health (excellent or
good/poor or very poor); suffers or has already suffered
some form of physical or emotional violence (yes/no);
has been forced to have intercourse (yes/no); uses
statins (yes/no); chronic disease: hypothyroidism
(yes/no); FSH (<40/≥40), LH (<25.7/≥25.7); age at
first sexual intercourse (≤19 years/≥20 years); other
type of sexual intercourse in the preceding month:
giving oral sex (yes/no), receiving oral sex (yes/no);
woman lives with sexual partner (yes/no); number of
sexual partners in the previous year (none/≥1); partner
underwent HIV testing (yes/no); quality of life following
diagnosis (changed/unchanged); CD4 cell count
(<350/≥350); CD4 cell count nadir (<199/≥200); use of
antiretroviral drug 3TC (lamivudine, Epivir; yes/no); use
of antiretroviral drug tenofovir (yes/no); use of anti-
retroviral drug lamivudine/zidovudine (yes/no); use of
antiretroviral drug efavirenz (yes/no); antiretroviral
drug used in the past: lamivudine/zidovudine (yes/no);
and antiretroviral drug used in the past: efavirenz (yes/
no). Menopausal status was classified as premenopausal,
perimenopausal or postmenopausal. Women were con-
sidered premenopausal if they continued to have
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regular menstrual cycles similar to those present during
the woman’s reproductive life. They were considered to
be in the perimenopause if their menstrual cycles were
irregular and they had been amenorrhoeic for less than
12 months. Finally, women were classified as postmeno-
pausal if they had been amenorrhoeic for 12 months or
more.14 Data on physical activity was obtained through
two questions: Do you practise physical exercise or par-
ticipate in sports every week? How often in a week do
you practise physical exercise or participate in sports? It
was classified in up to two times a week or three or more
times a week. Vaginal lubrication during sexual activity
was graded from 1 to 6, where 1 referred to the absence
of lubrication and 6 to maximum lubrication. This was
dichotomised into four or less or more than four.
Statistical analysis
A bivariate analysis was performed in which dyspareunia
was considered the dependent variable (dyspareunia)
and analysed as a function of the independent variables.
Pearson’s χ2 test and the Yates correction were used to
compare the groups.15 The Poisson multiple regression
analysis16 was adjusted in the various models for each
one of the independent variables to evaluate the factors
associated with the presence of dyspareunia.
Ethics
The study was approved by the internal review board of
CAISM/UNICAMP and was conducted in compliance
with the current version of the Declaration of Helsinki
and with Resolution 196/96 of the Brazilian National
Committee for Ethics in Research (CONEP) and its sub-
sequent revisions. This study forms part of a larger study
evaluating menopausal symptoms, bone mass, sexual
function and metabolic markers. Process: CEP: 407/
2010, CAAE 0313.0.146.000-10.
Women who agreed to participate in the study after
receiving instructions from the researchers and who
signed a free informed consent form were included.
RESULTS
The HIV-positive women were younger and less likely to
have a steady partner, to be employed or to have a
formal education compared with the HIV-negative
women. More than half the HIV-positive women were
premenopausal or perimenopausal. The characteristics
of the women interviewed are shown in table 1.
Overall, 41.4% (n=53) of the HIV-positive women and
34.8% (n=62) of the HIV-negative women reported dys-
pareunia. There was no association between HIV status
and dyspareunia (p=0.242). Furthermore, in the mul-
tiple regression analysis of the entire sample of
HIV-positive and HIV-negative women taken together
(n=306), dyspareunia was not associated with HIV status,
but was associated with vaginal dryness (prevalence ratio
(PR)=2.06, 95% CI 1.37 to 3.10, p=0.001) and urinary
incontinence (PR=1.68, 95% CI 1.14 to 2.46, p=0.008).
In the HIV-positive group, 91.4% of the women
were currently using ART, and of these 87% reported
using ART regularly (data not presented as a table).
Approximately 77% of the HIV-positive women had a CD4
cell count nadir >200. The most common way in which
HIV had been acquired was by heterosexual transmission,
and the average duration of the HIV infection was 9.5
±5.6 years (mean±SD), with a mean duration of therapy of
8.7 years±4.5 (mean±SD). A more detailed description of
the HIV-infected women is provided in table 2.
Bivariate analysis revealed an association between dys-
pareunia in the HIV-positive women and having a steady
partner (p=0.047); the woman’s partner having under-
gone HIV testing (p=0.020); vaginal dryness (p<0.001);
muscle/joint pain (p=0.021); physical/emotional vio-
lence (p=0.049); urinary incontinence (p=0.004); and
the use of lamivudine/zidovudine (p=0.048), table 3.
According to the Poisson multiple regression analysis,
the principal factors associated with dyspareunia in the
group of HIV-positive women were: vaginal dryness
(PR=1.96; 95% CI 1.10 to 3.50; p=0.023) and urinary
incontinence (PR=1.86; 95% CI 1.06 to 3.27; p=0.031;
table 4).
DISCUSSION
The objectives of this study were to evaluate whether
HIV status was associated with dyspareunia and to assess
the factors associated with pain during sexual inter-
course in HIV-positive women aged 40–60 years.
The calculated number of women required for the
sample size was 74 per group;4 however, to enable ana-
lysis of the HIV-positive group alone, the required
number was 188 women.17 Since the actual sample size
achieved was 128, the absolute difference was 8.5%,
acceptable since it is less than 10%.
Information on dyspareunia in HIV-positive women is
scarce, especially in middle-aged women. To the best of
our knowledge, no other studies have been conducted
on dyspareunia in HIV-positive women. It has been
reported that sexual function in HIV-positive women
may be driven principally by psychological factors and
other problems related to HIV infection.17 18 This study,
however, found that in the overall sample of HIV-positive
and HIV-negative women dyspareunia was not affected
by HIV status. This finding is in agreement with the
results of another author, who also reported that few
women believed HIV in itself to be the cause of any
decline in their sexual functioning, since those women
had good immunovirological status.10 One supposes that
results would be different in a sample of women without
good HIV control. In this study, more than three-
quarters of the HIV-positive patients had a CD4 cell
count nadir >200 and CD4 cell counts >500 in their last
evaluation, thus reflecting adequate control of the
disease. This may partially explain why no association
was found between HIV status and dyspareunia. In line
with this, another study showed that women with CD4
Valadares ALR, et al. BMJ Open 2014;4:e004974. doi:10.1136/bmjopen-2014-004974 3
Open Access
counts ≤199 cells/μL reported poorer sexual function-
ing compared with those whose cell count was ≥200.19
Other studies have shown that the CD4 cell count nadir
may also have long-term consequences in terms of prog-
nosis and mortality.20
Nevertheless, the CD4 cell count nadir and the last
CD4 evaluation were not associated with dyspareunia in
this study, probably because of the small number of
women with these low values.
The most important factors associated with dyspar-
eunia in the logistic regression analysis, in HIV-positive
and HIV-negative groups analysed together, and in the
HIV group analysis were vaginal dryness and urinary
incontinence, both of which are urogenital disorders
associated with oestrogen deficiency. The association
between vaginal dryness and pain during sexual inter-
course has been well documented in the literature, in
addition to its consequence on vulvovaginal health.21–23
With respect to the association between urinary incon-
tinence and dyspareunia, the findings of this study are
in agreement with the results published by Salonia
et al,24 who evaluated 216 women with urinary
incontinence and found 44% of dyspareunia in these
women. The type of urinary incontinence was not evalu-
ated in this study. Nevertheless, there is good evidence
that the effects of urinary incontinence on sexual func-
tioning are similar irrespective of whether the condition
has been classified as stress, urge, mixed incontinence25
or even interstitial cystitis.26 Urinary incontinence is asso-
ciated with feelings of embarrassment and inadequacy as
well as low self-esteem. It may also be associated with
dyspareunia.24
Factors associated with dyspareunia in HIV-positive
women:
In the bivariate analysis, the fact that the woman’s
partner had not been tested for HIV was associated with
less dyspareunia. It is reasonable to speculate that not
knowing her partner’s HIV status may in some way ‘min-
imise’ a woman’s concerns regarding transmission and
reduce the probability of tension and dyspareunia.27
Another factor related to the sexual partner that was
associated with an increase in dyspareunia in the bivari-
ate analysis was the woman having a steady partner,
although this association was borderline. One
Table 1 Some characteristics of women according to HIV status
Group
Characteristic HIV-infected (%; n=128) HIV-uninfected (%; n=178) p Value
Age (years)
40–44 43.8 24.7 <0.002*
45–49 28.9 29.2
50–54 15.6 23.1
≥55 11.7 23.0
Skin colour
White 35.2 47.2 0.047†
Non-white 64.8 52.8
Number of deliveries
Up to 1 25.0 25.4 >0.999†
≥2 75.0 74.6
Marital status
With partner 58.6 87.1 <0.001†
Without partner 41.4 12.9
Schooling (years)
≤7 62.5 40.4 <0.002*
8–11 23.4 37.1
≥12 14.1 22.5
Employment status
Yes 59.4 71.9 0.030†
No 40.6 28.1
Menopausal status
Premenopausal 39.8 24.7 <0.002*
Perimenopausal 28.1 21.4
Postmenopausal 32.1 53.9
Current smoking status
Yes/former 28.1 15.2 0.009†
No 71.9 84.8
Physical activity
Up to 2 times/week 77.3 74.2 0.614†
≥3 times/week 22.7 25.8
*Pearson’s χ2; and Yates’s χ2.
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explanation for this finding may lie in the psychological
problems generated by the infection itself, which may
arise more frequently in stable relationships.27 28 As one
has not controlled for frequency of intercourse, one
thought is that the dyspareunia is probably due a lower
frequency of intercourse rather than an inferior quality
of the relationship. Results of the bivariate analysis
revealed an association between physical/emotional vio-
lence and dyspareunia. Violence is known to be asso-
ciated with poorer psychological adjustment and adverse
sexual health outcomes in women.29 30 In addition,
having muscle pain was associated with dyspareunia in
the bivariate analysis. This finding is in line with another
study showing that musculoskeletal pain often interferes
with sex and may be associated with dyspareunia.31 A
borderline association was found between the use of
lamivudine/zidovudine and dyspareunia; however, no
explanation for this association was found in the litera-
ture. One may hypothesise that dyspareunia in these
women could be due to the side effects of these drugs
on depression.
There are some limitations to this study that must be
taken into account. First, its cross-sectional design does
not permit any conclusions to be drawn with respect to
causality. It is also important to note that it was a clinical
sample. So the results found in this study may not be
extrapolated to the general population. Furthermore,
there were some differences in the clinical character-
istics of the HIV-positive and HIV-negative women.
These differences could be attributed to the fact that
the HIV-negative women were selected at specialist out-
patient clinics providing care to menopausal women. By
selecting HIV-positive women also in menopausal out-
patient care, maybe groups would be similar.
Nevertheless, multivariate analysis, conducted in a suffi-
ciently large sample of women after controlling for con-
founding factors, confirmed that HIV infection was not
significantly associated with dyspareunia. Good control
of the HIV infection and the regular use of ART by the
majority of the women may have brought this group of
women closer to the HIV-negative group in terms of
their characteristics.
CONCLUSIONS
In this study population, HIV infection was not asso-
ciated with the presence of dyspareunia. The principal
factors associated with dyspareunia in HIV-positive
Table 2 Characteristics associated to HIV status
associated with dyspareunia in women with a sexual
partner in the month before the interview (n=128)
Characteristics N %
HIV duration of infection
(n=125; years)
Mean: 9.5 SD: 5.06
Duration of HIV therapy
(n=93; years)
Mean: 8.7 SD: 4.47
Nadir CD4 levels*
0–100 18 14.5
101–200 10 8.1
201–500 62 50.0
Last CD4 levels*
0–100 5 4.0
101–200 1 0.8
201–500 43 34.7
>500 75 60.5
Total 124 100.0
HIV risk factor for acquisition
Heterosexual acquisition 97 75.8
Illicit drug use 3 2.3
Blood transfusion 2 1.6
26 20.3
Total 128 100.0
Use of TARV
Yes 117 91.4
No 11 8.6
Total 128 100.0
*Missing information.
TARV, terapia anti-retroviral.
Table 3 Factors associated with dyspareunia (score ≥2)
in middle-aged HIV-positive women: bivariate analysis
Dyspareunia %
Variable n Score≥2 Score<2 p Value
Marital status 0.047
Married/live together 75 49.3 50.7
Do not live together 53 30.2 69.8
Did partner have an
HIV test?
0.020
Yes 88 50.0 50.0
No 27 22.2 77.8
Vaginal dryness <0.001
Yes 53 58.5 41.5
No 71 26.8 73.2
Muscular/articular pain 0.021
Yes 83 49.4 50.6
No 45 26.7 73.3
Physical/emotional
violence
0.049
Yes 128 55.5 44.5
No 174 32.8 67.2
Urinary incontinence 0.004
Yes 41 61.0 39.0
No 87 32.2 67.8
Use of biovir 0.048
Yes 57 29.8 70.2
No 63 49.2 50.8
Table 4 Variables associated with dyspareunia in
HIV-positive women with a sexual partner in the month
before the interview
Variable PR 95% CI p Value
Vaginal dryness 1.96 1.10 to 3.50 0.023
Urinary incontinence 1.86 1.06 to 3.27 0.031
Poisson multiple regression (n=124).
PR, prevalence ratio.
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women were vaginal dryness and urinary incontinence.
These data indicate a need for multidisciplinary care for
HIV-positive menopausal women, paying particular
attention to ensuring the women’s compliance with ART
and offering improved care when these two clinical
situations are present to ensure that these women come
as close as possible in this respect to HIV-negative
women. Greater attention to dyspareunia as a potential
component of women’s general HIV and sexual care is
warranted. A proactive approach to conversations about
vulvovaginal atrophy would improve the management of
dyspareunia and vaginal dryness. In addition to improv-
ing the quality of these women’s sexual lives, we
hypothesise that appropriate management of this issue
may reduce the likelihood of lesions on the vaginal wall,
which may act as a portal of entry for other infections.
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